⁸⁹Zr-immuno-PET using the anti-LAG-3 tracer [⁸⁹Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.

ABSTRACT:

Purpose

Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [⁸⁹Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration.

Methods

Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [¹⁸F]FDG-PET, patients were given 240 mg of BI 754091, followed 8 days later by administration o

SUBMITTER: Miedema IHC 

PROVIDER: S-EPMC10199858 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature